pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
← back to Sanofi
News mentioning $SNY
309
stories
12d
Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from China
fiercebiotech
14d
Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
fiercebiotech
14d
Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked November
biospace
15d
T-time: British biotech pours $133M into the pot for bispecifics
biospace
16d
The top 12 companies hiring in biopharma now
biospace
16d
T-Therapeutics secures $133M for cancer, autoimmune TCRs
endpoints
16d
Sanofi stops development of Nurix-partnered immune drug
biopharma dive
16d
Sanofi ends development of Nurix's STAT6 degrader
endpoints
16d
Sanofi’s axing of Nurix STAT6 program ‘not a target-related issue’
biospace
16d
Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
biospace
17d
Sanofi scraps STAT6 degrader from Nurix just 2 months after entering clinic
fiercebiotech
17d
T-Therapeutics raises $133M series B for bispecific pipeline with Big Pharma backers in tow
fiercebiotech
18d
AbbVie invests £120M in UK, including expanded R&D site
fiercebiotech
18d
Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience
biopharma dive
19d
STAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival Dupixent
stat
19d
Can Saudi Arabia's burgeoning biotech hub withstand geopolitical pressures?
biospace
21d
Sanofi may seek higher European drug prices, not withhold launches, under Trump deal
endpoints
21d
Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deck
biospace
21d
Sanofi targets late-phase and commercial M&A to offset looming Dupixent decline
biospace
21d
‘We need to do better,’ Alnylam CEO admits, as uncertainty looms over transthyretin franchise
biospace
21d
Sanofi has no plans for 'major restructuring' as Dupixent's patent cliff looms
endpoints
22d
New biotech Setara forms with $90M to take on Jazz’s bonus rare disease programs
biospace
22d
Sanofi considering ‘moonshot’ treatments as M&A targets to survive Dupixent patent cliff
fiercebiotech
22d
Dren Bio lands $350M to push rare blood cancer therapy toward market
biospace
23d
BioMarin inks up to $475M deal to challenge Fabry ERT incumbents
fiercebiotech
23d
8 companies hiring in New York
biospace
24d
Behind the scenes of 3 Big Pharma layoffs
biospace
24d
Alphabet’s GV is one of biotech’s most influential corporate investors
biospace
28d
STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials
stat
28d
Al Sandrock to step down as Voyager CEO; Insmed adds Paul Hudson to board
endpoints
← prev
page 2 of 11
next →